Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

01/10/18	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
23/07/18	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
10/07/18	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
21/06/18	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
28/05/18	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

03/12/18	TxCell : acquisition par Sangamo finalisée
27/11/18	TxCell : retrait obligatoire ce jeudi
26/11/18	TxCell : près de sept millions d'actions apportées à l'OPAS
23/11/18	TXCell : Sangamo Therapeutics dépasse les 90%
15/11/18	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.80%	+3.44%	+70.64%	+109.32%	73.25B
ARGENX SE	+17.12%	+11.50%	+54.42%	+87.30%	61.95B
INSMED INCORPORATED	+3.70%	-4.77%	+0.41%	+484.07%	28.02B
WUXI BIOLOGICS (CAYMAN) INC.	+5.46%	+5.87%	+57.03%	+21.55%	24.15B
BIONTECH SE	-1.60%	-1.29%	-19.31%	-19.10%	23.01B
PHARMAESSENTIA CORPORATION	-6.00%	+6.02%	+244.39%	+430.80%	18.35B
GENMAB A/S	+3.80%	+5.62%	+40.50%	-15.26%	19.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.92%	+2.46%	+21.20%	+556.36%	15.92B
EXELIXIS, INC.	+2.11%	-1.21%	+36.57%	+149.14%	12.96B
Average	+3.67%	+1.06%	+56.21%	+200.46%	30.79B
Weighted average by Cap.	+5.99%	+3.14%	+56.21%	+164.07%

TxCell Stock CBOE

Stocks

0QTN

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile

End-of-day quote CBOE
- ^EUR	-